Koff W C, Fogler W E, Gutterman J, Fidler I J
Cancer Immunol Immunother. 1985;19(2):85-9. doi: 10.1007/BF00199714.
Human recombinant gamma interferon (INF-gamma) activated human peripheral blood monocytes to a cytotoxic state capable of lysing adherent tumorigenic cells without harming normal cells. The efficiency of INF-gamma activation of monocytes is enhanced by encapsulating INF-gamma within liposomes: The minimum effective dose (MED) of free INF-gamma for monocyte activation was found to be 1-10 U/ml, per 10(5) monocytes, whereas the minimum dose for IFN-gamma encapsulated in liposomes was less than 0.0025 U. Monocytes treated with liposome-encapsulated INF-gamma retained their cytotoxic phenotype for much longer than do monocytes treated with free INF-gamma. Since liposomes can be passively targeted to cells of the reticuloendothelial system following IV administration, these findings suggest that liposome-encapsulated INF-gamma may have therapeutic potential that should be evaluated in vivo.
人重组γ干扰素(INF-γ)可将人外周血单核细胞激活至细胞毒性状态,使其能够裂解贴壁的致瘤细胞而不损害正常细胞。通过将INF-γ包裹在脂质体内可提高单核细胞对INF-γ的激活效率:每10⁵个单核细胞,游离INF-γ激活单核细胞的最小有效剂量(MED)为1-10 U/ml,而包裹在脂质体中的IFN-γ的最小剂量小于0.0025 U。用脂质体包裹的INF-γ处理的单核细胞保持其细胞毒性表型的时间比用游离INF-γ处理的单核细胞长得多。由于静脉给药后脂质体可被动靶向网状内皮系统的细胞,这些发现表明脂质体包裹的INF-γ可能具有治疗潜力,应在体内进行评估。